Pulmonary arterial hypertension (PAH) is a severe but treatable form of pre-capillary
pulmonary hypertension caused by pulmonary vascular remodelling. As a result of basic …

Pulmonary hypertension is a progressive and often fatal cardiopulmonary condition
characterised by increased pulmonary arterial pressure, structural changes in the pulmonary …

Substantial progress has been made in the management of pulmonary arterial hypertension
(PAH) in the past 25 years, but the disease remains life-limiting. Established therapies for …

Platelet-derived growth factor (PDGF) is one of the most important cytokines associated with
pulmonary vascular remodeling in pulmonary arterial hypertension (PAH). PDGF receptor …

The lack of curative options for pulmonary arterial hypertension drives important research to
understand the mechanisms underlying this devastating disease. Among the main identified …

Current management of patients with congenital heart disease has increased their survival
into adulthood. This is accompanied by potential cardiac complications, including pulmonary …

Pericyte dysfunction, with excessive migration, hyperproliferation, and differentiation into
smooth muscle-like cells contributes to vascular remodeling in Pulmonary Arterial …

The Sugen 5416/hypoxia (Su/Hx) rat model of pulmonary arterial hypertension (PAH)
demonstrates most of the distinguishing features of PAH in humans, including increased …

Treatment options for pulmonary arterial hypertension (PAH) have improved substantially in
the last 30 years, but there is still a need for novel molecules that can regulate the excessive …

Abstract Purpose of Review Traditionally viewed as a passive player in circulation, the right
ventricle (RV) has become a pivotal force in hemodynamics. RV failure (RVF) is a …